Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

Core Insights - Organon (NYSE: OGN) stock has remained stagnant since the last analysis in June, with second-quarter 2025 results showing only slight movement [1] Company Analysis - The second-quarter results for Organon were slightly disappointing, indicating a lack of significant growth or catalysts to drive the stock price upward [1] Investment Strategy - The focus is on value investing, targeting stocks that are undervalued and have potential catalysts within a one to two-year investment horizon [1]